{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:00:17Z","timestamp":1790841617592,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-09004-1","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:15:02Z","timestamp":1790770502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human \u03b3\u03b4 T cells"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4619","authenticated-orcid":false,"given":"Anna Maria","family":"Corsale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-0540","authenticated-orcid":false,"given":"Marta","family":"Di Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-3180","authenticated-orcid":false,"given":"Juan Pablo","family":"Cerapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-4545","authenticated-orcid":false,"given":"Elena","family":"Lo Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Pizzolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0099-2011","authenticated-orcid":false,"given":"Claudia","family":"Avellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1902-7510","authenticated-orcid":false,"given":"Costanza","family":"Dieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Marchiafava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6779-225X","authenticated-orcid":false,"given":"Laura","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-352X","authenticated-orcid":false,"given":"Francesco","family":"Dieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-5818","authenticated-orcid":false,"given":"Serena","family":"Meraviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"3","key":"9004_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40259-025-00712-6","volume":"39","author":"M Chen","year":"2025","unstructured":"Chen M, Zhou Y, Bao K, Chen S, Song G, Wang S. Multispecific antibodies targeting PD-1\/PD-L1 in cancer. BioDrugs. 2025, May;39(3):427\u201344. https:\/\/doi.org\/10.1007\/s40259-025-00712-6.","journal-title":"BioDrugs"},{"issue":"1","key":"9004_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trecan.2024.10.009","volume":"11","author":"K Adam","year":"2025","unstructured":"Adam K, Butler SC, Workman CJ, Vignali DAA. Advances in LAG3 cancer immunotherapeutics. Trends Cancer. 2025, Jan;11(1):37\u201348. https:\/\/doi.org\/10.1016\/j.trecan.2024.10.009.","journal-title":"Trends Cancer"},{"issue":"1","key":"9004_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022, Jan, 6;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"key":"9004_CR4","doi-asserted-by":"publisher","first-page":"115547","DOI":"10.1016\/j.ejca.2025.115547","volume":"225","author":"EJ Lipson","year":"2025","unstructured":"Lipson EJ, Stephen Hodi F, Tawbi H, Schadendorf D, Ascierto PA, Matamala L, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer (Oxford, Engl: 1990). 2025, Jul;225:115547. https:\/\/doi.org\/10.1016\/j.ejca.2025.115547.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"issue":"1","key":"9004_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025, May, 7;6(1):27. https:\/\/doi.org\/10.1186\/s43556-025-00267-6.","journal-title":"Mol Biomed"},{"issue":"1","key":"9004_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023, Sep, 5;16(1):101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"9004_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","volume":"74","author":"EC Sundstrom","year":"2025","unstructured":"Sundstrom EC, Huang X, Wiemer AJ. Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. ImmunotherapyCancer Immunol Immunother. 2025, Jul, 15;74(8):272. https:\/\/doi.org\/10.1007\/s00262-025-04128-7.","journal-title":"ImmunotherapyCancer Immunol Immunother"},{"issue":"9","key":"9004_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers17091408","volume":"17","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil V, Lee SW. Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies. Cancers. 2025, Apr, 23;17(9):1408. https:\/\/doi.org\/10.3390\/cancers17091408.","journal-title":"Cancers"},{"issue":"16","key":"9004_CR9","doi-asserted-by":"publisher","first-page":"1546717","DOI":"10.3389\/fimmu.2025.1546717","volume":"16","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. Front Immunol. 2025, Apr;16(16):1546717. https:\/\/doi.org\/10.3389\/fimmu.2025.1546717.","journal-title":"Front Immunol"},{"issue":"4","key":"9004_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/jleuko\/qiae023","volume":"115","author":"M Di Simone","year":"2024","unstructured":"Di Simone M, Corsale AM, Toia F, Shekarkar Azgomi M, Di Stefano AB, Lo Presti E, et al. Tumor-infiltrating \u03b3\u03b4 T cells as targets of immune checkpoint blockade in melanoma. J Leukoc Biol. 2024, Mar, 29;115(4):760\u201370. https:\/\/doi.org\/10.1093\/jleuko\/qiae023.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"9004_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1136\/gutjnl-2020-322101","volume":"70","author":"E Lo Presti","year":"2021","unstructured":"Lo Presti E, Corsale AM, Di Simone M, Dieli F, Meraviglia S. Characterisation of \u03b3\u03b4 T cells infiltrating colorectal cancer. Gut. 2021, May;70(5):1001\u201303. https:\/\/doi.org\/10.1136\/gutjnl-2020-322101.","journal-title":"Gut"},{"issue":"12","key":"9004_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/biology13121010","volume":"13","author":"G Accardi","year":"2024","unstructured":"Accardi G, Calabr\u00f2 A, Caldarella R, Caruso C, Ciaccio M, Di Simone M, et al. Immune-inflammatory response in lifespan-what role does it play in extreme longevity? A Sicilian semi- and Supercentenarians study. Biology. 2024, Dec, 4;13(12):1010. https:\/\/doi.org\/10.3390\/biology13121010.","journal-title":"Biology"},{"issue":"1","key":"9004_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12883-023-03255-x","volume":"23","author":"T Piccoli","year":"2023","unstructured":"Piccoli T, Castro F, La Bella V, Meraviglia S, Di Simone M, Salemi G, et al. Role of the immune system in amyotrophic lateral sclerosis. Analysis of the natural killer cells and other circulating lymphocytes in a cohort of ALS patients. BMC Neurol. 2023, Jun, 9;23(1):222. https:\/\/doi.org\/10.1186\/s12883-023-03255-x.","journal-title":"BMC Neurol"},{"issue":"1","key":"9004_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/imm.70035","volume":"177","author":"MJ Hayati","year":"2026","unstructured":"Hayati MJ, Yaghmoorian Khojini J, Khara F, Heydari A, Vousooghi N, Abootorabi SMS, et al. Gamma Delta T cells in the tumour microenvironment: a double-edged sword. Immunology. 2026, Jan;177(1):44\u201358. https:\/\/doi.org\/10.1111\/imm.70035.","journal-title":"Immunology"},{"issue":"1","key":"9004_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12967-023-04514-8","volume":"21","author":"Y Wang","year":"2023","unstructured":"Wang Y, Ji N, Zhang Y, Chu J, Pan C, Zhang P, et al. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of V\u03b39V\u03b42 T cells in glioblastoma. J Transl Med. 2023, Sep, 28;21(1):672. https:\/\/doi.org\/10.1186\/s12967-023-04514-8.","journal-title":"J Transl Med"},{"issue":"1","key":"9004_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12967-014-0310-2","volume":"12","author":"E Sumi","year":"2014","unstructured":"Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, et al. Effects of zoledronic acid and the association between its efficacy and \u03b3\u03b4T cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. J Transl Med. 2014, Dec;12(1):310. https:\/\/doi.org\/10.1186\/s12967-014-0310-2.","journal-title":"J Transl Med"},{"issue":"1","key":"9004_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-025-00762-6","volume":"13","author":"SG Cieslak","year":"2025","unstructured":"Cieslak SG, Shahbazi R. Gamma delta T cells and their immunotherapeutic potential in cancer. Biomark Res. 2025, Mar, 28;13(1):51. https:\/\/doi.org\/10.1186\/s40364-025-00762-6.","journal-title":"Biomark Res"},{"issue":"1","key":"9004_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2022.2147424","volume":"23","author":"AM Corsale","year":"2023","unstructured":"Corsale AM, Di Simone M, Dieli F, Meraviglia S. Where could gammadelta T cells take us in the treatment of cancer? Expert Opin Biol Ther. 2023, Jan, 2;23(1):1\u20135. https:\/\/doi.org\/10.1080\/14712598.2022.2147424.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"9004_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/cancers17071063","volume":"17","author":"N Subhi-Issa","year":"2025","unstructured":"Subhi-Issa N, Tovar Manzano D, Pereiro Rodriguez A, Sanchez Ramon S, Perez Segura P, Oca\u00f1a A. \u03b3\u03b4 T cells: game changers in immune cell therapy for cancer. Cancers. 2025, Mar, 21;17(7):1063. https:\/\/doi.org\/10.3390\/cancers17071063.","journal-title":"Cancers"},{"issue":"1","key":"9004_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z, et al. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Sig Transduct Target Ther. 2023, Nov, 22;8(1):434. https:\/\/doi.org\/10.1038\/s41392-023-01653-8.","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"9004_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021, Feb;18(2):427\u201339. https:\/\/doi.org\/10.1038\/s41423-020-0515-7.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"9004_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12967-019-1897-0","volume":"17","author":"X Chen","year":"2019","unstructured":"Chen X, Shang W, Xu R, Wu M, Zhang X, Huang P, et al. Distribution and functions of \u03b3\u03b4 T cells infiltrated in the ovarian cancer microenvironment. J Transl Med. 2019, Dec;17(1):144. https:\/\/doi.org\/10.1186\/s12967-019-1897-0.","journal-title":"J Transl Med"},{"issue":"1","key":"9004_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","volume":"16","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Niu C, Cui J. Gamma-delta (\u03b3\u03b4) T cells: Friend or foe in cancer development? J Transl Med. 2018 Dec;16(1):3. https:\/\/doi.org\/10.1186\/s12967-017-1378-2.","journal-title":"J Transl Med"},{"issue":"1","key":"9004_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1479-5876-12-45","volume":"12","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells. J Transl Med. 2014, Feb;12(1):45. https:\/\/doi.org\/10.1186\/1479-5876-12-45 PubMed PMID: 24528541; PubMed Central PMCID: PMC3926263.","journal-title":"J Transl Med"},{"issue":"1","key":"9004_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12967-024-05327-z","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Wu M, Yang Y, Wang Z, He S, Tian X, et al. \u03b3\u03b4 T cells and the PD-1\/PD-L1 axis: a love\u2013hate relationship in the tumor microenvironment. J Transl Med. 2024, Jun, 10;22(1):553. https:\/\/doi.org\/10.1186\/s12967-024-05327-z.","journal-title":"J Transl Med"},{"issue":"6","key":"9004_CR26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/cells11060964","volume":"11","author":"P Weimer","year":"2022","unstructured":"Weimer P, Wellbrock J, Sturmheit T, Oliveira-Ferrer L, Ding Y, Menzel S, et al. Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by \u03b3\u03b4 T cells in ovarian cancer. Cells. 2022 Mar 11;11(6):964. https:\/\/doi.org\/10.3390\/cells11060964.","journal-title":"Cells"},{"issue":"14","key":"9004_CR27","doi-asserted-by":"publisher","first-page":"1286097","DOI":"10.3389\/fimmu.2023.1286097","volume":"14","author":"J Schadeck","year":"2024","unstructured":"Schadeck J, Oberg HH, Peipp M, Hedemann N, Schamel WW, Bauerschlag D, et al. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3. Front Immunol. 2024, Jan;14(14):1286097. https:\/\/doi.org\/10.3389\/fimmu.2023.1286097.","journal-title":"Front Immunol"},{"issue":"4","key":"9004_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41590-023-01448-7","volume":"24","author":"C Rancan","year":"2023","unstructured":"Rancan C, Arias-Badia M, Dogra P, Chen B, Aran D, Yang H, et al. Exhausted intratumoral V\u03b42\u2212 \u03b3\u03b4 T cells in human kidney cancer retain effector function. Nat Immunol. 2023, Apr;24(4):612\u201324. https:\/\/doi.org\/10.1038\/s41590-023-01448-7.","journal-title":"Nat Immunol"},{"issue":"1","key":"9004_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s44321-025-00338-9","volume":"18","author":"E Catafal-Tardos","year":"2026","unstructured":"Catafal-Tardos E, Dachicourt L, Baglioni MV, Fares Da Silva MGF, Secci D, Donia M, et al. Dynamics of checkpoint receptors in \u03b3\u03b4 T cell subsets are associated with clinical response during anti-PD-1 immunotherapies. EMBO Mol Med. 2026, Jan, 15;18(1):5. https:\/\/doi.org\/10.1038\/s44321-025-00338-9.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"9004_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019, Mar;20(3):326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","journal-title":"Nat Immunol"},{"issue":"7","key":"9004_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018, Jul;24(7):978\u201385. https:\/\/doi.org\/10.1038\/s41591-018-0045-3.","journal-title":"Nat Med"},{"issue":"5","key":"9004_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020, May;52(5):825\u201341.e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014.","journal-title":"Immunity"},{"issue":"4","key":"9004_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, De Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018, Nov;175(4):998\u20131013.e20. https:\/\/doi.org\/10.1016\/j.cell.2018.10.038.","journal-title":"Cell"},{"issue":"12","key":"9004_CR34","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","volume":"51","author":"A Cossarizza","year":"2021","unstructured":"Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol. 2021, Dec;51(12):2708\u20133145. https:\/\/doi.org\/10.1002\/eji.202170126.","journal-title":"Eur J Immunol"},{"issue":"1","key":"9004_CR35","doi-asserted-by":"publisher","first-page":"1939518","DOI":"10.1080\/2162402X.2021.1939518","volume":"10","author":"JP Cerapio","year":"2021","unstructured":"Cerapio JP, Perrier M, Balan\u00e7a CC, Gravelle P, Pont F, Devaud C, et al. Phased differentiation of \u03b3\u03b4 T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers. OncoImmunology. 2021, Jan;10(1):1939518. https:\/\/doi.org\/10.1080\/2162402X.2021.1939518.","journal-title":"OncoImmunology"},{"issue":"8","key":"9004_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019, Aug;25(8):1251\u201359. https:\/\/doi.org\/10.1038\/s41591-019-0522-3.","journal-title":"Nat Med"},{"issue":"8","key":"9004_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015, Aug;15(8):486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"9004_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019, Nov;19(11):665\u201374. https:\/\/doi.org\/10.1038\/s41577-019-0221-9.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"9004_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","volume":"35","author":"A Schietinger","year":"2014","unstructured":"Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014, Feb;35(2):51\u201360. https:\/\/doi.org\/10.1016\/j.it.2013.10.001.","journal-title":"Trends Immunol"},{"issue":"9","key":"9004_CR40","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20150598","volume":"213","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J Exp Med. 2016 Aug 22;213(9):1819\u201334. https:\/\/doi.org\/10.1084\/jem.20150598.","journal-title":"J Exp Med"},{"issue":"1","key":"9004_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12967-025-07168-w","volume":"23","author":"M Liu","year":"2025","unstructured":"Liu M, Sun Z, Liang F, Yao R, Yang L, Nan D, et al. IL-17 + \u03b3\u03b4T cell: a new target in hyperbaric oxygen treatment reducing spinal cord injury. J Transl Med. 2025, Oct, 17;23(1):1124. https:\/\/doi.org\/10.1186\/s12967-025-07168-w.","journal-title":"J Transl Med"},{"issue":"3","key":"9004_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020, Mar;20(3):173\u201385. https:\/\/doi.org\/10.1038\/s41577-019-0224-6.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"9004_CR43","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","volume":"200","author":"KO Dixon","year":"2018","unstructured":"Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018, Apr, 15;200(8):3000\u201307. https:\/\/doi.org\/10.4049\/jimmunol.1700407.","journal-title":"J Immunol"},{"issue":"5","key":"9004_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo KVK. Lag-3, tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016, May;44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001.","journal-title":"Immunity"},{"issue":"1","key":"9004_CR45","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016, Feb, 17;7(1):10501. https:\/\/doi.org\/10.1038\/ncomms10501.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"9004_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015, Jan;160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033.","journal-title":"Cell"},{"key":"9004_CR47","doi-asserted-by":"publisher","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology. 2017, Jan, 2;6(1):e1249561. https:\/\/doi.org\/10.1080\/2162402X.2016.1249561.","DOI":"10.1080\/2162402X.2016.1249561"},{"issue":"11","key":"9004_CR48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019, Nov;20(11):1425\u201334. https:\/\/doi.org\/10.1038\/s41590-019-0512-0.","journal-title":"Nat Immunol"},{"issue":"5","key":"9004_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R\u03b1 recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002, Nov;17(5):537\u201347. https:\/\/doi.org\/10.1016\/S1074-7613(02)00429-6.","journal-title":"Immunity"},{"issue":"23","key":"9004_CR50","doi-asserted-by":"publisher","first-page":"11490","DOI":"10.3390\/ijms262311490","volume":"26","author":"JW Goldufsky","year":"2025","unstructured":"Goldufsky JW, Reyes AF, Heller AA, Leifheit ME, Albalawi MN, King NT, et al. IL-15 complexes combined with PD-1 blockade affect immune cell distribution, localization, and immune signatures in regressing versus non-regressing metastatic breast tumors. IJMS. 2025, Nov, 27;26(23):11490. https:\/\/doi.org\/10.3390\/ijms262311490.","journal-title":"IJMS"},{"key":"9004_CR51","doi-asserted-by":"publisher","unstructured":"Waldmann TA. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Invest Derm Symp P. 2013, Dec;16(1):S28\u201330. https:\/\/doi.org\/10.1038\/jidsymp.2013.8.","DOI":"10.1038\/jidsymp.2013.8"},{"issue":"1","key":"9004_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bbrc.2015.06.162","volume":"464","author":"EK Heon","year":"2015","unstructured":"Heon EK, Wulan H, Macdonald LP, Malek AO, Braunstein GH, Eaves CG, et al. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of tim-3 in breast cancer. Biochem Bioph Res Co. 2015, Aug;464(1):360\u201366. https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.162.","journal-title":"Biochem Bioph Res Co"},{"issue":"9","key":"9004_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2019.1634050","volume":"19","author":"E Lo Presti","year":"2019","unstructured":"Lo Presti E, Corsale AM, Dieli F, Meraviglia S. \u03b3\u03b4 cell-based immunotherapy for cancer. Expert Opin Biol Ther. 2019, Sep, 2;19(9):887\u201395. https:\/\/doi.org\/10.1080\/14712598.2019.1634050.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"9004_CR54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1186\/s12967-025-07259-8","volume":"23","author":"Y Chen","year":"2025","unstructured":"Chen Y, Niu S, Li YR, Yang L. Innovative gene engineering strategies to address tumor antigen escape in cell therapy. J Transl Med. 2025, Nov, 5;23(1):1227. https:\/\/doi.org\/10.1186\/s12967-025-07259-8.","journal-title":"J Transl Med"},{"issue":"3","key":"9004_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, D\u00e9chanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020, Mar;19(3):169\u201384. https:\/\/doi.org\/10.1038\/s41573-019-0038-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"9004_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos B, Mensurado S, Coffelt SB. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019, Jul;19(7):392\u2013404. https:\/\/doi.org\/10.1038\/s41568-019-0153-5.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"9004_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12967-018-1519-2","volume":"16","author":"L Xuan","year":"2018","unstructured":"Xuan L, Wu X, Qiu D, Gao L, Liu H, Fan Z, et al. Regulatory \u03b3\u03b4 T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. J Transl Med. 2018, Dec;16(1):144. https:\/\/doi.org\/10.1186\/s12967-018-1519-2.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-09004-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:39:13Z","timestamp":1790840353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-09004-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9004"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-09004-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Local Ethical Committee (CEL) Palermo 1 (No. 25, dated 30\/10\/2024) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all donors involved in the study, and samples were processed in anonymized form.","order":1,"name":"Ethics","label":"Ethics approval and consent to partecipate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1229"}}